UBS lowered the firm’s price target on Salesforce (CRM) to $320 from $340 and keeps a Neutral rating on the shares. A guidance reaffirmation for growth seems “most likely,” the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRM:
- Salesforce (NYSE:CRM) Expands Its Reach in Healthcare and Government Sectors
- Veeva has ‘meaningful’ Life Science head start over Salesforce, says Oppenheimer
- KeyBanc still expects Veeva to retain majority of CRM customers
- Takeda selects Salesforce Life Sciences Cloud for Customer Engagement
- Salesforce, GSA announce collaboration to lower price of Slack